News &amp; Updates

A survey conducted prior to resmetirom approval reports low rates of weight loss medication prescription due to low comfort potentially from lack of education despite strong beliefs that these drugs can benefit patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Weight loss medications rarely prescribed in patients with MASLD: study

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

Patient satisfaction is high during the first year following penile inversion vaginoplasty for functional outcomes and alleviation of gender dysphoria, a study has shown.

Patients who underwent gender-affirming surgery report satisfaction, reduced distress

No link between prenatal organophosphate pesticide exposure and autism-related traits in childhood

Prenatal exposure to organophosphate pesticides does not appear to contribute to an increased likelihood of having autism-related traits in childhood, according to a study.

No link between prenatal organophosphate pesticide exposure and autism-related traits in childhood

Atogepant tied to better outcomes in adults with migraine

01 Sep 2026 by

In a subgroup of patients with migraine who completed the full 24-week double-blind treatment period, referred to as treatment completers, treatment with atogepant is associated with greater improvements in clinical efficacy and functional endpoints than topiramate, according to a post hoc analysis of the TEMPLE trial presented at EAN 2026.

Atogepant tied to better outcomes in adults with migraine

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026 by

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026

Tenofovir-sparing ART carries HBV risks

Discontinuing tenofovir in antiretroviral therapy (ART) may expose people living with HIV to hepatitis B virus (HBV)-related risks, including reactivation in those previously exposed and infection in those who are susceptible, according to a systematic review and meta-analysis.

Tenofovir-sparing ART carries HBV risks

AI in dermatology education: Studies lack evidence on effectiveness

Artificial intelligence (AI) holds potential in dermatology education, but existing literature demonstrates high risk of bias, has small sample sizes, and is characterized by limited methodological rigour, according to a review by Singapore researchers. Furthermore, evidence to determine whether AI-based tool improve learning outcomes compared with standard educational approaches is lacking.

AI in dermatology education: Studies lack evidence on effectiveness

When to resume antithrombotic therapy after GIB?

Early resumption of antiplatelet therapy (APT) and anticoagulant therapy (ACT) ≤7 days after gastrointestinal bleeding (GIB) offers a favourable benefit–risk balance in patients with cardiovascular (CV) or cerebrovascular indications, according to a systematic review and meta-analysis conducted by researchers from the Chinese University of Hong Kong and Nanyang Technological University in Singapore.

When to resume antithrombotic therapy after GIB?

31 Aug 2026

Evolving patterns of antipsychotic use for schizophrenia over 21 years in HK

Over the last two decades, antipsychotic prescriptions for patients with schizophrenia shifted notably toward second-generation antipsychotics (SGAs), regardless of formulation, and antipsychotic polypharmacy became more prevalent, although overall use of antipsychotics remained stable, a 21-year longitudinal study has shown.

Evolving patterns of antipsychotic use for schizophrenia over 21 years in HK

31 Aug 2026

Women with PMOS at high risk of ASCVD

The risk of atherosclerotic cardiovascular disease (ASCVD) events increases by more than fourfold in the presence of polyendocrine metabolic ovarian syndrome (PMOS), according to a retrospective study from the US.

Women with PMOS at high risk of ASCVD